Chemical Structure (Pemfexy Figure 01)
Pemfexy Injection
Product Images NDC 42367-531
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Pemfexy (NDC 42367-531). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eagle Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pemfexy Figure 02)
The text describes the survival probability of patients treated with two different chemotherapy regimens (Pemfexy + Cisplatin and Gemcitabine + Cisplatin) using a graph with survival time in months on the x-axis and percentage of patients surviving on the y-axis. The data also includes the number of patients at risk for each regimen at various time intervals.*
Figure 2 (Pemfexy Figure 03)
This is a table of data that compares two different treatments for cancer: Pemfexy + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The data includes the number of patients at risk for each treatment and their respective survival times in months.*
Figure 3 (Pemfexy Figure 04)
This appears to be a table showing survival probability and time for two treatment options (Pomfexy + Cisplatin and Gomeitabine + Cisplatin) in cancer patients. The data shows the number of patients at risk over time for each treatment option.*
Figure 4 (Pemfexy Figure 05)
The text describes the "Survival Probability" of patients who took "Pemfexy" and "Placebo" in a clinical trial over a period of months. The numbers represent the counts of the patients who were still alive during the given month out of the initial groups of patients - "441" patients who took Pemfexy and "222" patients who took Placebo. The final column shows the number of patients at risk.*
Figure 5 (Pemfexy Figure 06)
The text appears to be a table showing survival probability and survival time for two different groups (Pomfoxy and Placebo). The numbers in the table might represent the number of study participants who survived over a certain period of time, but without additional information, it is unclear how to interpret the numbers. The last two rows show some numbers that are not related to the table itself, but their meaning is not clear.*
Figure 6 (Pemfexy Figure 07)
This appears to be a table showing the survival probability and patients at risk in a clinical trial for Pemfexy compared to placebo. The table also includes survival time in months for the patients in each group.*
Figure 7 (Pemfexy Figure 08)
This appears to be a table showing survival probability and patients at risk for two different groups (Pemfoxy and Placebo) over a certain survival time period, which is measured in months. However, without more information about what these groups are or what the purpose of the data is, it is difficult to provide a more specific description.*
Figure 8 (Pemfexy Figure 09)
The text is a survival probability chart that shows the probability of survival over time (in months) for patients receiving two different treatments. The treatments are Pemfexy + Cispl and Cisplatin. The chart also includes the number of patients at risk for each treatment at different time intervals.*
25mg/ml Vial Label (Pemfexy Figure 10)
This is a description of a drug with the NDC code 42367-531-33. The drug is called PEMFEAY, and it is a cytotoxic agent available in a multi-dose vial. The drug is meant for intravenous infusion after dilution, and it is important to use caution during handling and preparation. The recommended dosage can be found in the prescribing information, as well as information on dosing and dilution. The drug must be diluted further before administration and infused within 48 hours after preparation. The vial and the diluted solution should be refrigerated between 2°C and 8°C. The drug is marketed by Eagle Pharmaceuticals, Inc. as prescription-only.*
25mg/ml Vial Label (Pemfexy Figure 11)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
